Dr. park cdmo selects thermo fisher scientific to equip new viral vector manufacturing facility

Waltham, mass.--(business wire)--thermo fisher scientific inc., the world leader in serving science, today announced that dr. park, an emerging viral vector contract development and manufacturing organization (cdmo) based in south korea, has selected thermo fisher to provide advanced bioreactors and consumables for its newest facility. dr. park specializes in adeno-associated virus-based (aav-based) viral vector production and currently at 5,000 l per batch, producing up to 40 clinical-grade ba.
CDMO Ratings Summary
CDMO Quant Ranking